货币 / KYMR
KYMR: Kymera Therapeutics Inc
43.70
USD
0.87
(1.95%)
今日KYMR汇率已更改-1.95%。当日,交易品种以低点43.21和高点44.57进行交易。
关注Kymera Therapeutics Inc动态。实时报价将帮助您快速应对市场变化。通过在不同的时间周期之间切换,您可以按分钟、小时、天、周和月监控汇率趋势和动态。使用这些信息来预测市场变化并做出明智的交易决策。
- M5
- M15
- M30
- H1
- H4
- D1
- W1
- MN
KYMR新闻
- Zacks Kymera Surges 70% in 3 Months: Buy, Sell or Hold the Stock?
- Benzinga Synovus Financial, Gilead Sciences And More On CNBC's 'Final Trades' - iShares U.S. Financial ETF (ARCA:IYF), Gilead Sciences (NASDAQ:GILD)
- Investing Kymera Therapeutics stock price target lowered to $65 at Brookline Capital
- Investing Morgan Stanley initiates Kymera Therapeutics stock with Overweight rating
- Investing Kymera Therapeutics Q4 2024 slides: immunology pipeline advances with $600M cash infusion
- Investing Tuesday’s Insider Activity: Major Buys and Sells Shake Up Markets
- Investing Kymera Therapeutics (KYMR) director group buys $13.9 million in stock
- Investing Monday’s Insider Activity: Top Buys and Sells in US Stocks
- Investing Kymera Therapeutics: Baker Bros acquire $28.8m in shares
- Investing Kymera price target raised to $54 from $51 at BofA on pipeline updates
- Investing Kymera’s partnerships with Sanofi and Gilead drive value
- Investing Kymera Therapeutics Announces Pricing of $250 Million Public Offering
- Benzinga Tesla To Rally Around 45%? Here Are 10 Top Analyst Forecasts For Thursday - Apple (NASDAQ:AAPL), Alnylam Pharmaceuticals (NASDAQ:ALNY)
- Investing Kymera stock price target raised to $60 from $54 at H.C. Wainwright
- Investing Kymera Therapeutics price target lowered to $70 at Brookline Capital
- Investing Kymera Therapeutics launches $250 million public stock offering
- Investing Kymera Therapeutics stock falls after announcing $250 million offering
- Investing Kymera stock falls as Jefferies lowers price target on program shifts
- Seeking Alpha Kymera Shrugs Off Sanofi Bust With Gilead Deal - But There Are Caveats (NASDAQ:KYMR)
- Investing Kymera stock falls as Sanofi drops IRAK4 degrader for next-gen candidate
- Benzinga Gilead Bets On Kymera's CDK2 Molecular Glue Degrader For New Cancer Therapies - Gilead Sciences (NASDAQ:GILD), Sanofi (NASDAQ:SNY)
- Investing Sanofi to advance Kymera’s oral IRAK4 degrader KT-485 to clinical testing
- Seeking Alpha Tracking Baker Brothers Portfolio – Q1 2025 Update
- Investing Kymera at Goldman Sachs Conference: Pioneering Oral Protein Degraders
日范围
43.21
44.57
年范围
19.44
53.27
- 前一天收盘价
- 44.20
- 开盘价
- 44.57
- 卖价
- 43.70
- 买价
- 44.00
- 最低价
- 43.21
- 最高价
- 44.57
- 交易量
- 1.523 K
- 日变化
- -1.95%
- 月变化
- -2.93%
- 6个月变化
- 14.40%
- 年变化
- -6.18%
30 七月, 星期三
12:15
USD
- 实际值
- 104 K
- 预测值
- 57 K
- 前值
- -33 K
12:30
USD
- 实际值
- 3.0%
- 预测值
- 0.4%
- 前值
- -0.5%
12:30
USD
- 实际值
- 2.0%
- 预测值
- 3.6%
- 前值
- 3.8%
12:30
USD
- 实际值
- 2.5%
- 预测值
- 3.3%
- 前值
- 3.5%
12:30
USD
- 实际值
- 2.1%
- 预测值
- 3.1%
- 前值
- 3.7%
12:30
USD
- 实际值
- 1.4%
- 预测值
- 0.8%
- 前值
- 0.5%
12:30
USD
- 实际值
- 6.3%
- 预测值
- -1.5%
- 前值
- -3.1%
14:00
USD
- 实际值
- 预测值
- 1.6%
- 前值
- 1.8%
14:00
USD
- 实际值
- 预测值
- 9.6%
- 前值
- 1.1%
14:00
USD
- 实际值
- 预测值
- 前值
- 72.6
14:30
USD
- 实际值
- 预测值
- 0.914 M
- 前值
- -3.169 M
14:30
USD
- 实际值
- 预测值
- 0.114 M
- 前值
- 0.455 M
14:30
USD
- 实际值
- 预测值
- 0.738 M
- 前值
- -0.740 M
14:30
USD
- 实际值
- 预测值
- -0.004 M
- 前值
- 0.095 M
14:30
USD
- 实际值
- 预测值
- -0.111 M
- 前值
- 2.931 M
14:30
USD
- 实际值
- 预测值
- 0.915 M
- 前值
- 0.282 M
14:30
USD
- 实际值
- 预测值
- 0.608 M
- 前值
- 0.003 M
14:30
USD
- 实际值
- 预测值
- 0.879 M
- 前值
- -1.738 M
14:30
USD
- 实际值
- 预测值
- 前值
- 0.087 M
14:30
USD
- 实际值
- 预测值
- 前值
- 1.6%
18:00
USD
- 实际值
- 预测值
- 前值
18:00
USD
- 实际值
- 预测值
- 前值
- 4.50%
18:30
USD
- 实际值
- 预测值
- 前值